6BFT
Structure of Bevacizumab Fab mutant in complex with VEGF
Experimental procedure
Experimental method | SINGLE WAVELENGTH |
Source type | SYNCHROTRON |
Source details | AUSTRALIAN SYNCHROTRON BEAMLINE MX2 |
Synchrotron site | Australian Synchrotron |
Beamline | MX2 |
Temperature [K] | 100 |
Detector technology | CCD |
Collection date | 2015-03-13 |
Detector | ADSC QUANTUM 315r |
Wavelength(s) | 0.9537 |
Spacegroup name | P 1 21 1 |
Unit cell lengths | 83.279, 88.749, 106.676 |
Unit cell angles | 90.00, 111.87, 90.00 |
Refinement procedure
Resolution | 45.000 - 2.550 |
R-factor | 0.1727 |
Rwork | 0.170 |
R-free | 0.21990 |
Structure solution method | MOLECULAR REPLACEMENT |
Starting model (for MR) | 1bj1 |
RMSD bond length | 0.010 |
RMSD bond angle | 1.082 |
Data reduction software | XDS |
Data scaling software | Aimless |
Phasing software | PHASER |
Refinement software | PHENIX ((1.10.1_2155: ???)) |
Data quality characteristics
Overall | Outer shell | |
Low resolution limit [Å] | 45.000 | 2.640 |
High resolution limit [Å] | 2.550 | 2.550 |
Rpim | 0.056 | |
Number of reflections | 47223 | |
<I/σ(I)> | 11.6 | |
Completeness [%] | 99.8 | |
Redundancy | 5.2 | |
CC(1/2) | 0.816 |
Crystallization Conditions
crystal ID | method | pH | temperature | details |
1 | VAPOR DIFFUSION | 293 | 100 mM MES, 6.0, 225 mM ammonium sulfate, 13% PEG4000, 10% isopropanol |